Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trialKathleen N. Moore, Bradley J. Monk, Noelle Cloven et al.|The Lancet Oncology|2019Cited by 533
NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019Deborah K. Armstrong, Anita M. Engh, Ronald D. Alvarez et al.|Journal of the National Comprehensive Cancer Network|2019Cited by 332